blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3319955

EP3319955 - 6-AMINO-QUINOLINE-3-CARBONITRILS AS COT MODULATORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.10.2021
Database last updated on 05.10.2024
FormerThe patent has been granted
Status updated on  23.10.2020
FormerGrant of patent is intended
Status updated on  09.06.2020
FormerExamination is in progress
Status updated on  05.03.2019
FormerRequest for examination was made
Status updated on  13.04.2018
FormerThe international publication has been made
Status updated on  13.01.2017
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024 [2024/42]
Applicant(s)For all designated states
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404 / US
[2018/20]
Inventor(s)01 / BACON, Elizabeth, M.
c/o Gilead Sciences Inc.
333 Lakeside Drive
Foster City, CA 94404 / US
02 / BALAN, Gayatri
c/o Gilead Sciences Inc.
333 Lakeside Drive
Foster City, CA 94404 / US
03 / CHOU, Chien-hung
c/o Gilead Sciences Inc.
333 Lakeside Drive
Foster City, CA 94404 / US
04 / CLARK, Christopher, T.
c/o Gilead Sciences Inc.
333 Lakeside Drive
Foster City, CA 94404 / US
05 / COTTELL, Jeromy, J.
c/o Gilead Sciences Inc.
333 Lakeside Drive
Foster City, CA 94404 / US
06 / KIM, Musong
c/o Gilead Sciences Inc.
333 Lakeside Drive
Foster City, CA 94404 / US
07 / KIRSCHBERG, Thorsten, A.
c/o Gilead Sciences Inc.
333 Lakeside Drive
Foster City, CA 94404 / US
08 / LINK, John, O.
c/o Gilead Sciences Inc.
333 Lakeside Drive
Foster City, CA 94404 / US
09 / PHILLIPS, Gary
c/o Gilead Sciences Inc.
333 Lakeside Drive
Foster City, CA 94404 / US
10 / SCHROEDER, Scott, D.
c/o Gilead Sciences Inc.
333 Lakeside Drive
Foster City, CA 94404 / US
11 / SQUIRES, Neil, H.
c/o Gilead Sciences Inc.
333 Lakeside Drive
Foster City, CA 94404 / US
12 / STEVENS, Kirk, L.
c/o Gilead Sciences Inc.
333 Lakeside Drive
Foster City, CA 94404 / US
13 / TAYLOR, James, G.
c/o Gilead Sciences Inc.
333 Lakeside Drive
Foster City, CA 94404 / US
14 / WATKINS, William, J.
c/o Gilead Sciences Inc.
333 Lakeside Drive
Foster City, CA 94404 / US
15 / WRIGHT, Nathan, E.
c/o Gilead Sciences Inc.
333 Lakeside Drive
Foster City, CA 94404 / US
16 / ZIPFEL, Sheila, M.
c/o Gilead Sciences Inc.
333 Lakeside Drive
Foster City, CA 94404 / US
 [2018/20]
Representative(s)Schnappauf, Georg
ZSP Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
[2018/20]
Application number, filing date16741446.530.06.2016
[2018/20]
WO2016US40552
Priority number, dateUS201562189155P06.07.2015         Original published format: US 201562189155 P
US201562269061P17.12.2015         Original published format: US 201562269061 P
[2018/20]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017007694
Date:12.01.2017
Language:EN
[2017/02]
Type: A1 Application with search report 
No.:EP3319955
Date:16.05.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 12.01.2017 takes the place of the publication of the European patent application.
[2018/20]
Type: B1 Patent specification 
No.:EP3319955
Date:25.11.2020
Language:EN
[2020/48]
Search report(s)International search report - published on:EP12.01.2017
ClassificationIPC:C07D401/12, C07D401/14, C07D405/14, A61K31/4709, A61P29/00, A61P35/00, A61P37/00
[2018/20]
CPC:
C07D401/12 (EP,KR,US); A61K31/4192 (KR); A61K31/4725 (KR);
A61P1/04 (EP); A61P1/16 (EP); A61P11/00 (EP);
A61P11/06 (EP); A61P11/08 (EP); A61P17/06 (EP);
A61P19/02 (EP); A61P19/06 (EP); A61P21/04 (EP);
A61P25/00 (EP); A61P25/28 (EP); A61P29/00 (EP,KR);
A61P3/00 (EP); A61P3/10 (EP,KR); A61P31/04 (EP);
A61P35/00 (EP,KR); A61P35/02 (EP); A61P37/00 (EP);
A61P37/06 (EP); A61P43/00 (EP); A61P5/50 (EP);
A61P7/04 (EP); A61P7/06 (EP); C07D401/14 (EP,US);
C07D405/14 (EP,KR,US); C07D409/14 (EP,US); C07D413/12 (EP,KR,US);
C07D413/14 (EP,US); C07D417/14 (EP,KR,US); C07D453/02 (EP,KR,US);
C07F7/0814 (KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/20]
Extension statesBA05.02.2018
ME05.02.2018
Validation statesMA05.02.2018
MD05.02.2018
TitleGerman:6-AMINO-QUINOLINE-3-CARBONITRILDERIVATE ALS COT MODULATOREN[2020/23]
English:6-AMINO-QUINOLINE-3-CARBONITRILS AS COT MODULATORS[2018/20]
French:DERIVES DE 6-AMINO-QUINOLINE-3-CARBONITRILE COMME DES MODULATEURS DE COT[2020/23]
Former [2018/20]6-AMINO-CHINOLIN-3-CARBONITRILE ALS COT-MODULATOREN
Former [2018/20]6-AMINO-QUINOLINE-3-CARBONITRILES UTILISÉS COMME MODULATEURS DE LA KINASE COT
Entry into regional phase05.02.2018National basic fee paid 
05.02.2018Designation fee(s) paid 
05.02.2018Examination fee paid 
Examination procedure05.02.2018Amendment by applicant (claims and/or description)
05.02.2018Examination requested  [2018/20]
05.02.2018Date on which the examining division has become responsible
07.03.2019Despatch of a communication from the examining division (Time limit: M04)
01.07.2019Reply to a communication from the examining division
27.09.2019Despatch of a communication from the examining division (Time limit: M04)
30.01.2020Reply to a communication from the examining division
10.06.2020Communication of intention to grant the patent
16.10.2020Fee for grant paid
16.10.2020Fee for publishing/printing paid
16.10.2020Receipt of the translation of the claim(s)
Opposition(s)26.08.2021No opposition filed within time limit [2021/44]
Fees paidRenewal fee
27.06.2018Renewal fee patent year 03
27.06.2019Renewal fee patent year 04
29.06.2020Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU30.06.2016
AL25.11.2020
CY25.11.2020
DK25.11.2020
EE25.11.2020
FI25.11.2020
HR25.11.2020
LT25.11.2020
LV25.11.2020
MC25.11.2020
MK25.11.2020
MT25.11.2020
RO25.11.2020
RS25.11.2020
SM25.11.2020
BG25.02.2021
IS25.03.2021
LU30.06.2021
[2024/42]
Former [2024/22]HU30.06.2016
AL25.11.2020
CY25.11.2020
DK25.11.2020
EE25.11.2020
FI25.11.2020
HR25.11.2020
LT25.11.2020
LV25.11.2020
MC25.11.2020
MK25.11.2020
RO25.11.2020
RS25.11.2020
SM25.11.2020
BG25.02.2021
IS25.03.2021
LU30.06.2021
Former [2023/33]HU30.06.2016
AL25.11.2020
CY25.11.2020
DK25.11.2020
EE25.11.2020
FI25.11.2020
HR25.11.2020
LT25.11.2020
LV25.11.2020
MC25.11.2020
RO25.11.2020
RS25.11.2020
SM25.11.2020
BG25.02.2021
IS25.03.2021
LU30.06.2021
Former [2023/30]AL25.11.2020
CY25.11.2020
DK25.11.2020
EE25.11.2020
FI25.11.2020
HR25.11.2020
LT25.11.2020
LV25.11.2020
MC25.11.2020
RO25.11.2020
RS25.11.2020
SM25.11.2020
BG25.02.2021
IS25.03.2021
LU30.06.2021
Former [2022/18]AL25.11.2020
DK25.11.2020
EE25.11.2020
FI25.11.2020
HR25.11.2020
LT25.11.2020
LV25.11.2020
MC25.11.2020
RO25.11.2020
RS25.11.2020
SM25.11.2020
BG25.02.2021
IS25.03.2021
LU30.06.2021
Former [2022/08]AL25.11.2020
DK25.11.2020
EE25.11.2020
FI25.11.2020
HR25.11.2020
LT25.11.2020
LV25.11.2020
MC25.11.2020
RO25.11.2020
RS25.11.2020
SM25.11.2020
BG25.02.2021
IS25.03.2021
Former [2021/45]AL25.11.2020
DK25.11.2020
EE25.11.2020
FI25.11.2020
HR25.11.2020
LT25.11.2020
LV25.11.2020
RO25.11.2020
RS25.11.2020
SM25.11.2020
BG25.02.2021
IS25.03.2021
Former [2021/37]DK25.11.2020
EE25.11.2020
FI25.11.2020
HR25.11.2020
LT25.11.2020
LV25.11.2020
RO25.11.2020
RS25.11.2020
SM25.11.2020
BG25.02.2021
IS25.03.2021
Former [2021/36]EE25.11.2020
FI25.11.2020
HR25.11.2020
LT25.11.2020
LV25.11.2020
RO25.11.2020
RS25.11.2020
SM25.11.2020
BG25.02.2021
IS25.03.2021
Former [2021/35]FI25.11.2020
HR25.11.2020
LT25.11.2020
LV25.11.2020
RO25.11.2020
RS25.11.2020
SM25.11.2020
BG25.02.2021
IS25.03.2021
Former [2021/33]FI25.11.2020
HR25.11.2020
LT25.11.2020
LV25.11.2020
RS25.11.2020
SM25.11.2020
BG25.02.2021
IS25.03.2021
Former [2021/32]FI25.11.2020
HR25.11.2020
LV25.11.2020
RS25.11.2020
SM25.11.2020
BG25.02.2021
IS25.03.2021
Former [2021/28]FI25.11.2020
HR25.11.2020
LV25.11.2020
RS25.11.2020
BG25.02.2021
IS25.03.2021
Former [2021/25]FI25.11.2020
LV25.11.2020
RS25.11.2020
BG25.02.2021
IS25.03.2021
Former [2021/24]FI25.11.2020
LV25.11.2020
RS25.11.2020
BG25.02.2021
Former [2021/23]FI25.11.2020
LV25.11.2020
RS25.11.2020
Former [2021/22]FI25.11.2020
RS25.11.2020
Former [2021/20]FI25.11.2020
Cited inInternational search[A]WO2006124692  (WYETH CORP [US], et al) [A] 1-48 * see the preferred compounds and especially all examples as inhibitors of TPL2 kinase *;
 [A]  - RAKESH K GOYAL ET AL, "Models for anti-inflammatory activity of 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles", MEDICINAL CHEMISTRY RESEARCH, BIRKHÄUSER-VERLAG, BOSTON, (20110319), vol. 21, no. 7, doi:10.1007/S00044-011-9613-5, ISSN 1554-8120, pages 1044 - 1055, XP035060999 [A] 1-48 * see the compounds of table 1 as inhibitors of TPL2 kinase *

DOI:   http://dx.doi.org/10.1007/s00044-011-9613-5
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.